SCYNEXIS INC: management transactions · United States · SEC (Form 4)

About SCYNEXIS INC

SCYNEXIS, Inc. (ticker: SCYX) is a U.S.-listed biotechnology company traded on the NASDAQ market in the United States. The company is positioned as a developer of innovative medicines for difficult-to-treat and drug-resistant infections, with a historical emphasis on antifungal therapy and, more recently, a strategic tilt toward severe rare diseases. SCYNEXIS was formed as a Delaware corporation in 1999 and is headquartered in Jersey City, New Jersey. In its recent filings and corporate communications, the company describes itself as a clinical-stage biotech focused on addressing significant unmet medical needs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001178253/000095017025038044/scyx-20241231.htm?utm_source=openai)) For much of its corporate history, SCYNEXIS has been centered on ibrexafungerp, marketed as BREXAFEMME®, an oral, non-azole antifungal. This product represented an important therapeutic advance in the treatment of certain vaginal yeast infections, and the company has also explored broader anti-infective applications for the molecule. More recently, SCYNEXIS has signaled a broader pipeline strategy beyond its antifungal foundation, highlighting programs such as SCY-247 and SCY-770 in severe rare disease areas. That evolution suggests a company trying to build a more diversified long-term pipeline around proprietary science and niche clinical needs. ([nasdaq.com](https://www.nasdaq.com/press-release/scynexis-announces-u.s.-availability-of-brexafemmer-ibrexafungerp-tablets-the-first?utm_source=openai)) From a competitive standpoint, SCYNEXIS remains a small-cap biopharma company and therefore carries the typical profile of this segment: high scientific risk, regulatory uncertainty, dependence on external capital, and meaningful execution risk around development and commercialization. Its differentiation lies in its antifungal know-how, its first-in-class or novel-mechanism positioning in certain indications, and its potential to unlock value through partnerships. The company’s relatively modest employee base also underscores a lean operating model, consistent with a development-stage biotech rather than a fully scaled commercial pharma company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001178253/000095017025038044/scyx-20241231.htm?utm_source=openai)) Recent developments are especially relevant for investors. In 2025 and 2026, SCYNEXIS reported progress on transferring the BREXAFEMME NDA to GSK in connection with a potential relaunch, while also advancing its internally controlled programs. The company has emphasized SCY-770 and SCY-247 in recent updates, indicating a pipeline reorientation toward rare disease opportunities. On the capital markets side, Nasdaq granted SCYNEXIS a 180-day extension to regain compliance with the minimum bid price requirement, which points to continued share-price pressure. Taken together, these developments make SCYNEXIS a speculative but potentially interesting biotech story, with upside tied primarily to clinical execution, regulatory milestones, and strategic partnering. ([ir.scynexis.com](https://ir.scynexis.com/news-events/press-releases/detail/347/scynexis-reports-second-quarter-2025-financial-resultsand?utm_source=openai))